Jiangsu Hengrui Pharmaceuticals highlights its global oncology R&D capabilities with 64 research abstracts presented at the 2026 ESMO congress in Madrid.
Hengrui Medicine's presentation of 64 research abstracts at the 2026 ESMO Congress serves as a significant indicator of its robust oncology R&D capabilities. This high volume of scientific output underscores the company's strategic focus on global expansion and its commitment to advancing its international clinical pipeline.
Hengrui presented a record total of 64 research abstracts at the congress.
The research is primarily focused on oncology, highlighting the company's strength in cancer research and development.
Jiangsu Hengrui Pharmaceuticals showcased its robust oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) congress. The company presented a record 64 research abstracts, signaling a significant expansion of its international clinical development footprint.
Hengrui presented a record 64 research abstracts, demonstrating the depth of its oncology R&D and its commitment to global clinical development.